Everything below concerns Reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
=== Stable isotopes === Stable lutetium can be used as catalysts in petroleum cracking in refineries and can also be used in alkylation, hydrogenation, and polymerization applications. Lutetium aluminium garnet (Al5Lu3O12) has been proposed for use as a lens material in high refractive index immersion lithography. Additionally, a tiny amount of lutetium is added as a dopant to gadolinium gallium garnet, which was used in magnetic bubble memory devices. Cerium-doped lutetium oxyorthosilicate is currently the preferred compound for detectors in positron emission tomography (PET). Lutetium aluminium garnet (LuAG) is used as a phosphor in light-emitting diode light bulbs. Lutetium tantalate (LuTaO4) is the densest known stable white material (density 9.81 g/cm3) and therefore is an ideal host for X-ray phosphors. The only denser white material is thorium dioxide, with density of 10 g/cm3, but the thorium it contains is radioactive. Lutetium is also a compound of several scintillating materials, which convert X-rays to visible light. It is part of LYSO, LuAG and lutetium iodide scintillators. Research indicates that lutetium-ion atomic clocks could provide greater accuracy than any existing atomic clock.
Hazard research is published: an analysis of GBD study data shows pre-50 early-onset cancer cases rose by ~80% in 30 years (5 Sep), a study shows decoupling rates in high-income countries are inadequate for Paris Agreement commitments and suggests post-growth approaches such as demand reduction strategies and reorienting the economy (5 Sep), evidence of impacts of chronic and extreme heat exposure during pregnancy accumulates (7 Sep), a study shows early prevention of type 2 diabetes may save many years of life (11 Sep), a study estimates around 5 million adults died from cardiovascular disease due to lead exposure in 2019 (11 Sep), shortly after a review about biodiversity-related harmful effects on ecosystems by non-native ant invasions (29 Jul), the fifth-costliest invasive species, the red fire ant, is reported to have established itself in the warming Europe via colonies in Sicily (11 Sep), a product testing study shows cleaning products emit substantial amounts of hazardous VOCs, such as chloroform, with the lowest quantities in green fragrance-free products (12 Sep), the planetary boundaries framework assessment gets updated, incorporating freshwater change as a sixth Earth system dimension above its capacity limit (13 Sep), news outlets report on a study (31 Aug) that shows daily aspartame consumption leads to heritable cognitive deficits in mice – and more broadly that the exposome of men may also affect the mental health of the next generation (19 Sep), a study reports an increasing global exposure to air pollution from fires (20 Sep).
Homosexual acts are prohibited by law in Ghana. According to a 2013 survey by the Pew Research Center, 96% of Ghanaians believe that homosexuality should not be accepted by society. In 2026 further laws were introduced creating a duty to report homosexual acts and to criminalise "supporters" of LGBTQ+ people. Sometimes elderly women in Ghana are accused of witchcraft, particularly in rural Ghana. Issues of witchcraft mainly remain as speculations based on superstitions within families. In some parts of northern Ghana witch camps exist. These are said to house a total of around 1,000 people accused of and ostracised for witchcraft. The Ghanaian government announced that it intended to close the camps. Over a decade later, in 2023, the Anti-Witchcraft bill passed in parliament, to address accusations and the social impacts of being accused of being a witch, and the president refused to sign it into law. The legislation was reintroduced in 2025.
Sources: en.wikipedia.org
=== Distribution === The apparent oral volume of distribution (VSS/F) at steady state of (R)-bicalutamide with oral administration of a single 5 to 80 mg dose of (R)-bicalutamide in a novel solid dispersion with a polymeric matrix of hydroxypropyl methylcellulose phthalate (HP55S) (also known as (R)-bicalutamide/HP55S) ranges from 22.53 ± 3.71 L to 25.38 ± 2.69 L. Bicalutamide is highly protein-bound (96.1% for racemic bicalutamide, 99.6% for (R)-bicalutamide), mainly to albumin. It has negligible affinity for SHBG and no affinity for corticosteroid-binding globulin. The tissue distribution of bicalutamide is not well-characterized. However, it has been reported that distribution studies with bicalutamide have shown that preferential (i.e., tissue-selective) accumulation in anabolic (e.g., muscle) tissues does not occur. There are no available data on hepatic bicalutamide concentrations in humans, but a rat study found that oral bicalutamide treatment resulted in 4-fold higher concentrations of the drug in the liver relative to plasma (a common finding with orally administered drugs, due to transfer through the hepatic portal system prior to reaching circulation). In men receiving 150 mg/day bicalutamide, concentrations of (R)-bicalutamide in semen were 4.9 μg/mL (11 μmol/L), and the amount of the drug that could potentially be delivered to a female partner during sexual intercourse is regarded as low (estimated at 0.3 μg/kg) and below the amount that is required to induce changes in the offspring of laboratory animals.
is a quotient of activity coefficients. To avoid the complications involved in using activities, dissociation constants are determined, where possible, in a medium of high ionic strength, that is, under conditions in which
== Plants and bacteria == Although they lack neurons, systems responding to stimuli (analogous to the sensory system in animals with a nervous system, which includes the proprioception) have also been described in some plants (angiosperms). Terrestrial plants control the orientation of their primary growth through the sensing of several vectorial stimuli such as the light gradient or the gravitational acceleration. This control has been called tropism. A quantitative study of shoot gravitropism demonstrated that, when a plant is tilted, it cannot recover a steady erected posture under the sole driving of the sensing of its angular deflection versus gravity. An additional control through the continuous sensing of its curvature by the organ and the subsequent driving an active straightening process are required. Being a sensing by the plant of the relative configuration of its parts, it has been called proprioception. This dual sensing and control by gravisensing and proprioception has been formalized into a unifying mathematical model simulating the complete driving of the gravitropic movement. This model has been validated on 11 species sampling the phylogeny of land angiosperms, and on organs of very contrasted sizes, ranging from the small germination of wheat (coleoptile) to the trunk of poplar trees. Further studies have shown that the cellular mechanism of proprioception in plants involves myosin and actin, and seems to occur in specialized cells. Proprioception was then found to be involved in other tropisms and to be central also to the control of nutation.
Sources: en.wikipedia.org
CBO reported that net interest on the public debt was approximately $240 billion in FY2016 (6% of spending), an increase of $17 billion or 8% versus FY2015. A higher level of debt coincided with higher interest rates. During FY2012, the GAO reported a figure of $245 billion, down from $251 billion. Government also accrued a non-cash interest expense of $187 billion for intragovernmental debt, primarily the Social Security Trust Fund, for a total interest expense of $432 billion. GAO reported that even though the national debt rose in FY2012, the interest rate paid declined. Should interest rates rise to historical averages, the interest cost would increase dramatically. As of January 2012, public debt owned by foreigners has increased to approximately 50% of the total or approximately $5.0 trillion. As a result, nearly 50% of the interest payments are now leaving the country, which is different from past years when interest was paid to U.S. citizens holding the public debt. Interest expenses are projected to grow dramatically as the U.S. debt increases and interest rates rise from very low levels to more typical historical levels.
The sandwich or indirect ELISA provides a solution to this problem by using a "capture" antibody specific for the test antigen to pull it out of the serum's molecular mixture. ELISA may be run in a qualitative or quantitative format. Qualitative results provide a simple positive or negative result (yes or no) for a sample. The cutoff between positive and negative is determined by the analyst and may be statistical. Two or three times the standard deviation (error inherent in a test) is often used to distinguish positive from negative samples. In quantitative ELISA, the optical density (OD) of the sample is compared to a standard curve, which is typically a serial dilution of a known-concentration solution of the target molecule. For example, if a test sample returns an OD of 1.0, the point on the standard curve that gave OD = 1.0 must be of the same analyte concentration as the sample. The use and meaning of the names "indirect ELISA" and "direct ELISA" differ in the literature and on websites depending on the context of the experiment. When the presence of an antigen is analyzed, the name "direct ELISA" refers to an ELISA in which only a labeled primary antibody is used, and the term "indirect ELISA" refers to an ELISA in which the antigen is bound by the primary antibody which then is detected by a labeled secondary antibody. In the latter case, a sandwich ELISA is clearly distinct from an indirect ELISA. When the "primary" antibody is of interest, e.g.
In the summer before the election, polling showed at least half of Americans thought that Trump, who was 78 years old, was too old to serve a second term, with 80% unsure he would be able to finish out a second term. Numerous public figures, media sources, and mental health professionals speculated that Trump may have some form of dementia, which runs in his family. Experts for the science publication STAT who analyzed changes in Trump's speeches between 2015 and 2024 noted shorter sentences, more tangents, more repetition, and more confusion of words and phrases. Doctors suggested these changes could relate to Trump's moods or could indicate the beginning of Alzheimer's. One expert noted an increase in expressions of all-or-nothing thinking by Trump; a sharp rise in all-or-nothing thinking is also linked to cognitive decline. The New York Times reported that Trump's 2024 speeches had grown "darker, harsher, longer, angrier, less focused, more profane and increasingly fixated on the past", and that experts considered this increase in tangential speech and behavioral disinhibition as a possible consequence of advancing age and cognitive decline. Trump was also criticized for his lack of transparency around his medical records and health.
=== EC 1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors === EC 1.14.11.1: γ-butyrobetaine dioxygenase EC 1.14.11.2: procollagen-proline dioxygenase EC 1.14.11.3: pyrimidine-deoxynucleoside 2′-dioxygenase EC 1.14.11.4: procollagen-lysine 5-dioxygenase EC 1.14.11.5: Now included with EC 1.14.11.6 thymine dioxygenase EC 1.14.11.6: thymine dioxygenase EC 1.14.11.7: procollagen-proline 3-dioxygenase EC 1.14.11.8: trimethyllysine dioxygenase EC 1.14.11.9: flavanone 3-dioxygenase EC 1.14.11.10: pyrimidine-deoxynucleoside 1′-dioxygenase EC 1.14.11.11: hyoscyamine (6S)-dioxygenase EC 1.14.11.12: gibberellin-44 dioxygenase EC 1.14.11.13: gibberellin 2β-dioxygenase EC 1.14.11.14: Now EC 1.14.20.13, 6β-hydroxyhyoscyamine epoxidase EC 1.14.11.15: gibberellin 3β-dioxygenase EC 1.14.11.16: peptide-aspartate β-dioxygenase EC 1.14.11.17: taurine dioxygenase EC 1.14.11.18: phytanoyl-CoA dioxygenase EC 1.14.11.19: Now EC 1.14.20.4, anthocyanidin synthase EC 1.14.11.20: deacetoxyvindoline 4-hydroxylase EC 1.14.11.21: clavaminate synthase EC 1.14.11.22: Now EC 1.14.20.5, flavone synthase EC 1.14.11.23: Now EC 1.14.20.6, flavonol synthase EC 1.14.11.24: 2′-deoxymugineic-acid 2′-dioxygenase EC 1.14.11.25: mugineic-acid 3-dioxygenase EC 1.14.11.26: deacetoxycephalosporin-C hydroxylase EC 1.14.11.27: [histone H3]-dimethyl-L-lysine36 demethylase EC 1.14.11.28: proline 3-hydroxylase EC 1.14.11.29: hypoxia-inducible factor-proline dioxygenase EC 1.14.11.30: hypoxia-inducible factor-asparagine dioxygenase EC 1.14.11.31: thebaine 6-O-demethylase EC 1.14.11.32: codeine 3-O-demethylase EC 1.14.11.33: DNA oxidative demethylase EC 1.14.11.34: Now EC 1.14.20.7, 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.11.35: 1-deoxypentalenic acid 11β-hydroxylase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.37: kanamycin B dioxygenase EC 1.14.11.38: verruculogen synthase EC 1.14.11.39: L-asparagine hydroxylase EC 1.14.11.40: enduracididine β-hydroxylase EC 1.14.11.41: L-arginine hydroxylase EC 1.14.11.42: tRNAPhe (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase EC 1.14.11.43: (S)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.44: (R)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.45: L-isoleucine 4-hydroxylase EC 1.14.11.46: 2-aminoethylphosphonate dioxygenase EC 1.14.11.47: [50S ribosomal protein L16]-arginine 3-hydroxylase EC 1.14.11.48: xanthine dioxygenase EC 1.14.11.49: uridine-5′-phosphate dioxygenase EC|1.14.11.50: Now EC 1.14.20.8, (–)-deoxypodophyllotoxin synthase EC 1.14.11.51: DNA N6-methyladenine demethylase EC 1.14.11.52: validamycin A dioxygenase EC 1.14.11.53: mRNA N6-methyladenine demethylase EC 1.14.11.54: mRNA N1-methyladenine demethylase EC 1.14.11.55: ectoine hydroxylase EC 1.14.11.56: L-proline cis-4-hydroxylase EC 1.14.11.57: L-proline trans-4-hydroxylase EC 1.14.11.58: ornithine lipid ester-linked acyl 2-hydroxylase EC 1.14.11.59: 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.11.60: scopoletin 8-hydroxylase EC 1.14.11.61: feruloyl-CoA 6-hydroxylase EC 1.14.11.62: trans-4-coumaroyl-CoA 2-hydroxylase EC 1.14.11.63: peptidyl-lysine (3S)-dioxygenase EC 1.14.11.64: glutarate dioxygenase EC 1.14.11.65: [histone H3]-dimethyl-L-lysine9 demethylase EC 1.14.11.66: [histone H3]-trimethylL-lysine9 demethylase EC 1.14.11.67: [histone H3]-trimethyl-LL-lysine4 demethylase EC 1.14.11.68: [histone H3]-trimethyl-L-lysine27 demethylase EC 1.14.11.69: [histone H3]-trimethyl-L-lysine37 demethylase EC 1.14.11.70: 7-deoxycylindrospermopsin hydroxylase EC 1.14.11.71: methylphosphonate hydroxylase EC 1.14.11.72: [2-(trimethylamino)ethyl]phosphonate dioxygenase EC 1.14.11.73: [protein]-arginine 3-hydroxylase EC 1.14.11.74: L-isoleucine 31-dioxygenase EC 1.14.11.75: 31-hydroxy-L-isoleucine 4-dioxygenase EC 1.14.11.76: L-glutamate 3(R)-hydroxylase EC 1.14.11.77: alkyl sulfatase
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.